Oncology Central

Are there, or shall we discover, biomarkers to guide PD-1 inhibition?


The most important application of biomarkers in cancer immunotherapy is the potential to identify and select patients who are most likely to respond. Unfortunately, we know that not all patients respond to immunotherapy. If we take the example of ipilimumab, 20% of patients achieve a long-term benefit, another 60% have a benefit which can be of a few (3–4) months or longer (1–2 years), while for the other 20% – treatment has no beneficial effect [1]. Clearly, it would be helpful to know which one of these three different groups a patient belongs to before deciding on whether to treat with ipilimumab.

To view restricted content, please:

Leave A Comment